On September 28, director Norman Payson completed a transaction in which he sold 6,618 shares in Progyny, Inc. (NASDAQ: PGNY). The shares were sold for a total value of $257,572.56, and buyers were willing to pay an average price of $38.92 per share. As a direct result of the transaction, the director now owns 358,468 shares of the company’s stock. Based on the current market price, these shares have an approximate value of $13,951,574.56. In addition, the Securities and Exchange Commission was provided with legal documentation regarding the transaction. You’ll be able to view the entire thing if you follow the link in the previous sentence and click on it.
In addition, Norman Payson recently completed the following deals not too long ago:
During the lunchtime session on Friday, NASDAQ: PGNY shares were trading $1.59 lower at $37.06 per share. There were 652,099 shares traded, which is lower than the stock’s daily volume of 741,795, the average number of shares traded. Progyny, Inc.’s lowest price in the past year is $25.67, while the company’s all-time high was $68.32. The company’s current valuation of $3.41 billion is based on several metrics, including its price-to-earnings ratio of 82.52, PEG ratio of 9.28, and beta value of 1.67. All of these metrics contribute to the company’s overall value. In addition, moving averages for the past 50 days come in at $39.32 for the company while moving averages for the past 200 days come in at $37.76.
Progyny (NASDAQ: PGNY) announced the results of its most recent financial report covering the previous quarter on Thursday, August 4. The company reported earnings per share (EPS) for the quarter at $0.09, which is $0.07 more than the consensus estimate of $0.02 per share. Even though market watchers anticipated that the company would bring in sales of $190.51 million for the quarter, the company brought in sales of $195 million instead. The return on equity for Progyny was 17.11 percent, while the net margin for the company was 7.39 percent. The revenue that Progyny brought in during the most recent quarter was significantly higher by 51.5% compared to the same quarter the year before. Compared to the previous year’s results for the same quarter, the company’s earnings per share came in at $0.19. Sell-side analysts think Progyny, Inc. will make 0.2 cents per share in profit during the current fiscal year.
Recent transactions involving the purchase and sale of PGNY shares have included participation from various institutional investors and hedge funds. The National Bank of Canada Financial Institutional increased the amount of money it had invested in Progyny by $29,000 during the year’s second quarter. During the first quarter, Lazard Asset Management LLC spent $62,000 to acquire Progyny. The transaction took place. Castle Wealth Management LLC increased its holdings in Progyny during the second quarter by investing an additional $63,000 to purchase company shares. During the first three months of this year, Exane Derivatives acquired a new position in Progyny worth $69,000 in investments. Not to be outdone, during the first three months of this year, Parkside Financial Bank & Trust invested $75,000 into a new holding in the business Progyny. The company’s stock makes up 88.64% of all institutional investors’ holdings.
Research analysts have discussed PGNY in various reports they have produced throughout their careers. For example, the results of a study report on sexism directed toward women available to the general public on September 7 by Truist Financial. They suggested investing in the stock at $56.00 and establishing a price goal for the stock at $56.00. On September 15, KeyCorp made a research note on progeny available online to anyone interested in reading it. They gave the stock an “overweight” rating and decided that a price target of $55.00 was appropriate for it. Six equity research experts have suggested to investors that they should purchase the stock, while only one has suggested that investors continue to hold onto it. According to data provided by Bloomberg, the stock has been recommended “Moderate Buy,” and most analysts have agreed that the price target is $65.83.
The benefits management company, Progyny, Inc., focuses most of its efforts on providing family planning and fertility benefits for employers in the United States. The company’s solution for fertility benefits includes a different kind of benefit plan, a network of fertility experts, and member support services like concierge services.
Source: beststocks.com
